<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://www.pharmanow.live/latest-news/ideaya-biosciences-fda-type-c-ide849-registrational-strategy-neuroendocrine-carcinomas</loc>
    <lastmod>2026-11-17T11:33:56+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>IDEAYA Biosciences Secures FDA Type C Alignment on Dual-Track IDE849 Registrational Strategy in Neuroendocrine Carcinomas</news:title>
      
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/5df6c963-339a-4a99-a8d8-0a4b0725a073/a0bb65c0-13a9-401f-aad1-56b032942e98.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/genentech-fda-approval-giredestrant-everolimus-esr1-mutated-metastatic-breast-cancer</loc>
    <lastmod>2026-11-17T11:34:54+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Genentech Gains FDA Approval for Giredestrant Plus Everolimus in Breast Cancer</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/5df6c963-339a-4a99-a8d8-0a4b0725a073/02cb588b-28b7-46d1-98a9-aeea1c75d067.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/cue-biopharma-phase-2-csu-durability-data-cue-401-first-in-human-dosing</loc>
    <lastmod>2026-11-17T11:36:45+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Cue Biopharma Reports Phase 2 CSU Durability Data and CUE-401 First-in-Human Dosing</news:title>
      
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://www.globenewswire.com/newsroom/ti?nf=OTg3ODg4MyM3OTY5NTI3IzIwOTI2OTI=</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/mankind-pharma-signs-exclusive-india-deal-betta-pharmaceuticals-ensartinib-alk-nsclc</loc>
    <lastmod>2026-11-17T11:35:42+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Mankind Pharma Signs Exclusive India Deal with Betta Pharmaceuticals</news:title>
      <news:keywords>Mankind</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/bf9c78ec-f5fb-44f9-8827-7c34bfabed8b/287bf348-5120-42ad-a63c-cf7dc1a073c2.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/lantheus-achieves-phase-3-endpoints-tauklarify-tau-pet-early-alzheimers</loc>
    <lastmod>2026-11-17T11:27:12+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Lantheus Achieves Phase 3 Endpoints for TAUKLARIFY in Early Alzheimer's Disease</news:title>
      <news:keywords>Lantheus</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://www.globenewswire.com/newsroom/ti?nf=OTg3NzQ2MSM3OTY1MjI3IzIwMDc2OTA=</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/ucb-fda-approval-klygefa-dual-binding-nanobody-c5-inhibitor-gmg</loc>
    <lastmod>2026-11-17T11:29:01+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>UCB Gains FDA Approval for Klygefa as First Dual-Binding Nanobody C5 Inhibitor</news:title>
      <news:keywords>UCB</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/bf9c78ec-f5fb-44f9-8827-7c34bfabed8b/2981ecf6-4533-40b9-bcba-3c3ded747cc1.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/novartis-cosentyx-chmp-positive-opinion-adolescent-hidradenitis-suppurativa-europe</loc>
    <lastmod>2026-11-17T11:25:38+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T00:00:00+05:30</news:publication_date>
      <news:title>Novartis Gains CHMP Positive Opinion for Cosentyx in Adolescent Hidradenitis Suppurativa</news:title>
      <news:keywords>Novartis</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/8dedc9d6-b11e-478f-9cfc-0079d66f9dce/93aa2a78-dc06-43e3-b627-d1ae45b24dd6.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/evotec-secures-2-9-million-gates-foundation-grant-stem-cell-fetal-safety-screening</loc>
    <lastmod>2026-11-17T11:24:24+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T00:00:00+05:30</news:publication_date>
      <news:title>Evotec Secures $2.9 Million Gates Foundation Grant to Extend Stem Cell-Based Fetal Safety Screening</news:title>
      <news:keywords>Evotec</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/86c356d2-28ef-40dc-9d30-9ccc4328d3a7/ac34f7a8-d2ee-4659-9589-487827303b70.png</image:loc>
    </image:image>
  </url>
</urlset>